What was the average price Cosmos Health paid per share in this buyback?

As of the filing date (August 19, 2026), Cosmos Health paid approximately $0.217 per share, calculated from 5,112,000 shares repurchased for $1.11 million. This includes Q2 repurchases of 2,650,000 shares for $513,000 and continued open market purchases into Q3.

When does the $5M repurchase authorization expire?

The Board-authorized program expires December 31, 2026, and is renewable at the Company's sole discretion. The authorization is not tied to any specific date trigger or performance milestone, giving management flexibility to continue buybacks if they choose to renew.

How much of the $5M authorization remained unused as of the filing date?

Approximately $3.89 million remained available under the authorization as of August 19, 2026, after $1.11 million had been deployed in the first six weeks of the program. This represents roughly 78% of the budget still available for deployment through year-end.

What was Cosmos Health's financial condition when it authorized the buyback?

The Company had strengthened its balance sheet in H1 2026, reducing total liabilities by $6.27 million (13.3%) and increasing stockholders' equity by 12.2% to $20.67 million. Liquid assets totaled $4.15 million (cash and marketable securities). Revenue grew 29.7% year-over-year in the first half to $36.91 million.

Will Cosmos Health complete the full $5M repurchase before year-end 2026?

The filing does not provide guidance on whether the Company intends to deploy the full authorization or at what pace. At the current rate of approximately $0.56 million per month (based on Q2 plus early Q3 activity), completion of the full $5M program would require acceleration or continuation into year-end.

COSM 8-K Filed 2026-08-20 New authorization

Cosmos Health initiates $5M share repurchase program

Board authorizes buyback through Dec. 31, 2026; 5.1M shares already repurchased for $1.11M as of filing date.

Authorization$5M

Remaining$4M

MechanismOpen market purchases under Ru

What the filing says

Cosmos Health Inc. (NASDAQ: COSM) authorized a share repurchase program of up to $5.0 million on June 26, 2026, expiring December 31, 2026 and renewable at the Company's sole discretion. The program will execute through open market purchases under Rule 10b-18.

By the filing date (August 19, 2026), Cosmos Health had already repurchased 5,112,000 shares for approximately $1.11 million, comprising 2,650,000 shares for $513,000 in Q2 2026 and continued repurchases into Q3 2026. The average price paid was approximately $0.217 per share, leaving approximately $3.89 million remaining under the authorization.

In CEO Greg Siokas's commentary, management stated: "We began buying back our own stock because we believe our shares trade well below the underlying value of our diversified asset base and growth prospects." The buyback announcement coincided with strong operational performance, including record Q2 2026 revenue of $18.99 million (up 29% year-over-year) and a balance sheet improvement that reduced total liabilities by $6.27 million and increased stockholders' equity by 12.2% to $20.67 million in the first half of 2026.

This authorization represents management's confidence in Cosmos Health's valuation and capital position. At the average execution price of $0.217 per share, the company has deployed approximately 22% of its $5M authorization in roughly two months. The buyback's scale relative to stockholders' equity ($20.67M as of June 30, 2026) is modest—the $1.11M spent to date represents about 5.4% of equity—but demonstrates capital discipline at a time when the company is reporting strong revenue growth and improving operational metrics. The program expires December 31, 2026, allowing roughly four months for execution. No guidance is provided on whether the full $5M will be deployed or whether the program will be renewed.

On June 26, 2026, the Company's Board of Directors authorized a share repurchase program of up to $5.0 million, expiring December 31, 2026 and renewable at the Company's sole discretion. Cosmos Health repurchased 2,650,000 shares for approximately $513,000 during the second quarter, and open market purchases have continued into Q3 2026, bringing total repurchases as of this date to 5,112,000 shares for approximately $1.11 million. — Cosmos Health Inc. 8-K filing · View on SEC EDGAR →

What this means

Frequently asked questions

What was the average price Cosmos Health paid per share in this buyback?: As of the filing date (August 19, 2026), Cosmos Health paid approximately $0.217 per share, calculated from 5,112,000 shares repurchased for $1.11 million. This includes Q2 repurchases of 2,650,000 shares for $513,000 and continued open market purchases into Q3.
When does the $5M repurchase authorization expire?: The Board-authorized program expires December 31, 2026, and is renewable at the Company's sole discretion. The authorization is not tied to any specific date trigger or performance milestone, giving management flexibility to continue buybacks if they choose to renew.
Why did Cosmos Health's CEO say management initiated the buyback?: CEO Greg Siokas stated that the Company 'began buying back our own stock because we believe our shares trade well below the underlying value of our diversified asset base and growth prospects.' This reflects management's belief that the stock is undervalued relative to the company's assets and future earnings potential.
How much of the $5M authorization remained unused as of the filing date?: Approximately $3.89 million remained available under the authorization as of August 19, 2026, after $1.11 million had been deployed in the first six weeks of the program. This represents roughly 78% of the budget still available for deployment through year-end.
What was Cosmos Health's financial condition when it authorized the buyback?: The Company had strengthened its balance sheet in H1 2026, reducing total liabilities by $6.27 million (13.3%) and increasing stockholders' equity by 12.2% to $20.67 million. Liquid assets totaled $4.15 million (cash and marketable securities). Revenue grew 29.7% year-over-year in the first half to $36.91 million.
Will Cosmos Health complete the full $5M repurchase before year-end 2026?: The filing does not provide guidance on whether the Company intends to deploy the full authorization or at what pace. At the current rate of approximately $0.56 million per month (based on Q2 plus early Q3 activity), completion of the full $5M program would require acceleration or continuation into year-end.

authorization rule-10b-18 execution open-market healthcare q2-2026

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.